3. Querol-Ribells JM, Tenias JM, Grau E, et al. Plasma d-dimer levels correlate with outcomes in patients with community-acquired pneumonia. Chest, 2004, 126(4):1087-1092.
[4]
4. Snijders D, Schoorl M, Schoorl M, et al. D-dimer levels in assessing severity and clinical outcome in patients with community-acquired pneumonia. A secondary analysis of a randomised clinical trial. Eur J Intern Med, 2012, 23(5): 436-441.
10. Yadav R, Prasad K, Padma VM, et al. Influence of socioeconomic status on in-hospital mortality and morbidity after stroke in India: retrospective hospital-based cohort study. Indian J Community Med, 2013, 38(1):39-41.
[11]
11. Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med, 2001, 29(7 Suppl): S99-S106.
[12]
12. Sharpe BA. Putting a critical pathway into practice: the devil is in the implementation details: comment on effect of “a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia”. Arch Intern Med, 2012, 172(12):928-929.
[13]
13. Kins TC, Sakai J, Knepper BC, et al. Risk factors for drug-resistant streptococcus pneumoniae and antibiotic prescribing practices in outpatient community-acquired pneumonia. Acad Emerg Med, 2012, 19(6):703-706.
